INTRODUCTION
============

High blood pressure has been associated with cardiovascular risk and mortality ([@b14-jer-14-4-671]; [@b26-jer-14-4-671]), and this disease is considered a major public health problem, with worldwide prevalence rate around one billion and increasing direct healthcare costs ([@b18-jer-14-4-671]; [@b24-jer-14-4-671]; [@b28-jer-14-4-671]). Furthermore, previous studies demonstrated that hypertensive subjects have several dysfunctions on the autonomic nervous system (ANS) and vascular tissue ([@b12-jer-14-4-671]; [@b17-jer-14-4-671]), generating the increase of blood pressure. On the other hand, regular exercise has been effective in preventing this disease and is strongly recommended for hypertension treatment ([@b2-jer-14-4-671]; [@b7-jer-14-4-671]; [@b7-jer-14-4-671]).

Regarding the ANS, heart rate variability (HRV) is an accepted method to analyze changes on the ANS, which describes the oscillations in the interval between consecutive heart beats and it can provide information about the behavior of sympathetic and parasympathetic components of the ANS ([@b32-jer-14-4-671]). There is a relationship between reductions of HRV at rest with ventricular arrhythmias and sudden cardiac death ([@b30-jer-14-4-671]; [@b38-jer-14-4-671]; [@b39-jer-14-4-671]) as well as increased in morality risk ([@b21-jer-14-4-671]). HRV also can be used to evaluate cardiovascular overload and stress induced by exercise ([@b3-jer-14-4-671]; [@b33-jer-14-4-671]). In addition, the evaluation of HRV during exercise recovery is essential to determine clinical interventions for individuals with cardiovascular disease, once after exercise occurs reductions in HRV ([@b4-jer-14-4-671]), which is considered a critical period to development of arrhythmias, ischemia, ectopic heart activity and sudden cardiac death in cardiac patients ([@b19-jer-14-4-671]; [@b23-jer-14-4-671]; [@b35-jer-14-4-671]).

Previous studies showed that acute aerobic exercise can reduce the blood pressure, a condition denominated postexercise hypotension (PEH), which has an important contribution in controlling high blood pressure ([@b10-jer-14-4-671]; [@b29-jer-14-4-671]). Studies demonstrated that during exercise recovery period, the combination of sustained postexercise vasodilatation with reduction in sympathetic nerve activity as well as increasing parasympathetic tone contributes considerably for PEH ([@b10-jer-14-4-671]; [@b13-jer-14-4-671]; [@b22-jer-14-4-671]). In this context, nutritional interventions with effects on vasodilatation and autonomic modulation may potentiate fall in arterial blood pressure after exercise.

It has been investigated the influence of oral adenosine-5'-triphosphate (ATP) supplementation on resistance exercise performance, demonstrating ergogenic effects ([@b9-jer-14-4-671]; [@b31-jer-14-4-671]; [@b41-jer-14-4-671]). The great interest of ATP supplementation can be associated with physiological effects of extracellular ATP on skeletal muscle excitability and vascular tissue. During exercise, under conditions of low oxygen availability in the muscle, red blood cells release ATP to bind at purinergic receptor P2Y, increasing the synthesis of vasodilator substances (nitric oxide, prostaglandin, and endothelial-derived hyperpolarization factors), thus maximizing vasodilation and blood flow in the skeletal muscle ([@b5-jer-14-4-671]; [@b11-jer-14-4-671]; [@b25-jer-14-4-671]). Although oral ATP supplementation likely does not increase the bioavailability of extracellular ATP ([@b1-jer-14-4-671]), a study with animals conducted by [@b20-jer-14-4-671] found that chronic ATP administration enhanced ATP uptake and synthesis in the erythrocyte, suggesting that ATP supplementation can increase ATP levels in erythrocyte and this may enhance vasodilatation and blood flow.

Regarding the cardiovascular system, it is not clear at the literature about the effects of ATP supplementation. [@b15-jer-14-4-671] demonstrated that ATP supplementation increased blood flow after resistance exercise in animals and humans, and they suggested that the vasodilation effect by extracellular ATP could explain the increased of blood flow. Given that the vasodilatation can reduce blood pressure ([@b13-jer-14-4-671]; [@b16-jer-14-4-671]) and ATP supplementation increased blood flow after exercise in humans ([@b15-jer-14-4-671]), improvements in PEH in hypertensive patients with ATP supplementation may be plausible. In addition, whether ATP supplementation can influence autonomic recovery after exercise is unknown in the literature.

Thus, the aim of this study was to verify the autonomic modulation and blood pressure after ATP supplementation associated to acute aerobic exercise in hypertensive women. We hypothesized that a single dose of ATP supplementation could potentiate PEH and improved autonomic parameters recovery in hypertensive women.

MATERIALS AND METHODS
=====================

Experimental design
-------------------

This study used a randomized, double-blind design. Participants completed two experimental trials in the laboratory, which was separated by seven days. To ensure chronobiological control, all experimental trials were performed at the same period of the day (in the morning). The first visit included anthropometric measurements. During the following two visits, each participant consumed either the placebo or ATP supplementation randomly, and then completed 30 min of aerobic exercise. The blood pressure and HRV were evaluated. The experimental design is presented in [Fig. 1](#f1-jer-14-4-671){ref-type="fig"}.

Subjects
--------

The study included eleven hypertensive women who were submitted to two experimental trials, separated by seven days. To be included in the study the participants had to meet the following criteria: (a) have medical diagnosis of hypertension and permission to participate in the training; (b) absence of health problems that could prevent the completion of the assessments and exercise interventions (i.e., absence of limbs, hurting joints); (c) to not use supplementation during the study or other substances (vitamins). The participants were instructed to not take any medicine before each experimental trial. After being informed of the risks and benefits involved in the study, the participants signed a consent form. The project was approved by the Ethics Research Group of the University of São Judas, São Paulo-SP, Brazil (protocol number: 66523717.2.0000.0089) and the research was conducted according to the 2008 Revision of the Declaration of Helsinki.

Procedures
----------

### Anthropometric measurements

Anthropometry was composed of body weight and height measurements. Height was measured with a fixed-stadiometer, Sanny brand, with an accuracy of 0.1 cm and a length of 2.20 m. Body weight was measured using an electronic scale (Sanny brand, São Paulo, Brazil), with a precision of 0.1 kg. Subsequently, the body mass index was calculated (BMI=weight \[kg\]/height^2^ \[m\]).

### Supplementation protocol and dietary intake

Each participant ingested randomly either: 400 mg of oral ATP supplementation (ProMera Health LLC, Norwell, MA, USA -- 200 mL: 400-mg adenosine-5'-triphosphate disodium) or placebo (Clight Juice, Kraft Foods, São Paulo, Brazil - 200 mL: energy 21 kj, 5 kcal, sodium 4.7 mg). Supplementation or placebo was ingested 30 min before exercise supplied in identical bottles. To ensure double-blind design, we chose this specific juice (Clight) as placebo due to flavor similarity with ATP supplement ([@b9-jer-14-4-671]).

All participants were required to answer a food questionnaire reporting their dietary intake (breakfast) before the exercise protocol. To ensure that dietary intake was similar between the trials, participants were instructed to replicate the first trial's dietary intake in the subsequent trial. Data were analyzed by the same nutritionist using NutWin software ver. 1.5 (a program for assisting nutrition by the Federal University of São Paulo, Brazil, 2002) and total kilocalories intake (kcal) and macronutrient in grams (carbohydrates, lipids, and protein) were identified. During the study, all participants were instructed not to use any other supplementation or ergogenic substances (i.e., caffeine), as well as make changes to their regular diet.

Blood pressure and autonomic modulation measurements
----------------------------------------------------

Blood pressure was recorded at rest, immediately post-exercise, post-10, post-20 and post-30 min after exercise. The systolic and diastolic blood pressure were measurement using automatic blood pressure monitor (Omron Healthcare brand Inc., Intellisense, Model HEM 742 INT, Bannockburn, IL, USA) previously validated ([@b6-jer-14-4-671]).

The autonomic modulation was recorded at rest for 30 min, and during recovery (postexercise until 30 min after exercise). It was measured through HRV and expressed by time and frequency domains. Subjects were instructed to remain in silence, awake, at rest, breathing spontaneously in the supine position. After the procedures had been explained, an elastic strap was placed at the height of the xiphoid process of the subject and a heart rate (HR) receptor on the wrist (Polar Electro, model S810i or RS800, Kempele, Finland). This equipment has been previously validated to record beat-to-beat HR and HRV analysis ([@b37-jer-14-4-671]), and the same procedures were conducted on both days of the test.

The temporal recording of the interval between consecutive cardiac beats (RR) was submitted to digital filtering complemented by manual filtering using the Polar software. Only sets with more than 95% sinoatrial node beats were included in this study. After this, intervals of 5 min were analyzed in Kubios software (Biosignal Analysis and Medical Image Group, Department of Physics, University of Kuopio, Kuopio, Finland) ([@b36-jer-14-4-671]). For time domain, the analysis included the square root of the mean squared difference between adjacent RR intervals (RMSSD), standard deviation of all normal RR intervals (SDNN). For frequency domain, the analysis included spectral components of low frequency (LF: frequency between 0.04 and 0.15 Hz) and high frequency (HF: frequency between 0.15 to 0.4 Hz) expressed in normalized units. Spectral analysis was calculated using Fast Fourier Transform ([@b36-jer-14-4-671]).

Exercise protocol
-----------------

Before the exercise protocol, subjects completed a warm-up, which consisted of 5 min of walking. After this, the participants performed 30 min of moderate to vigorous aerobic exercise on a track according to the recommendation of the American College of Sports Medicine ([@b27-jer-14-4-671]). Participants were instructed to walk or run maintaining HR between 70%--75% of maximum HR. The HR was recorded using a digital stopwatch (model S810i; Polar Electro, Kempele, Finland). After exercise, all subjects laid down for 30 min to perform the hemodynamic and autonomic modulation procedures. All training sessions were conducted under the supervision of physical education professionals and students who had been previously familiarized with the training program.

Statistical analysis
--------------------

The average of 30 min during recovery was calculated for HRV and blood pressure. A repeated measures analysis of variance with Bonferroni adjustment for multiple comparisons was used to compare HRV mean and blood pressure mean according to three different conditions (rest, ATP, and placebo). For all measured variables, the estimated sphericity was verified according to Mauchly's W test, and the Greenhouse--Geisser correction was used when necessary. Furthermore, delta was calculated for HRV (Δ=recovery minus rest) and blood pressure (Δ=post-20 min minus rest). The comparison of the delta was performed using the Student *t*-test for dependent samples. Statistical significance was set at *P*\<0.05. The effect size (eta-squared=*η*^2^) test was calculated for time. Data were analyzed using Stata 10 (StataCorp LP., College Station, TX, USA).

RESULTS
=======

[Table 1](#t1-jer-14-4-671){ref-type="table"} presents values of mean and standard deviation for age, body weight, height, dietary intake pre-exercise and exercise intensity during two experimental trials. For exercise intensity, no significant difference was observed between trials.

[Table 2](#t2-jer-14-4-671){ref-type="table"} shows the differences in HR and autonomic modulation according to temporal and frequency domain between placebo and ATP condition. For HR (bpm) there was a main effect of time (*F*=19.249, *P*\<0.001, *η*^2^=0.68) with higher HR for placebo and ATP in relation to rest, however, no significant difference were observed between trials.

For RMSSD, there was statistically significant difference during recovery (*F*=4.917, *P*=0.020, *η*^2^=0.35), with significant higher RMSSD for ATP compared to placebo (*P*=0.027). When analyzed SDNN, there was no statistically significant difference (*F*=2.414, *P*=0.118, *η*^2^=0.21), however, Bonferroni *post hoc* demonstrated significant greater SNDD in the ATP conditions compared to placebo (*P*=0.041).

Regarding frequency domain (LFmsec^2^ and HFmsec^2^), there were no significant difference during recovery (*P*\>0.05). For LFnu, HFnu, and LF/HF ratio, there were no statistically significant difference during recovery between conditions (*P*\>0.05).

[Fig. 2](#f2-jer-14-4-671){ref-type="fig"} shows the delta (Δ=recovery minus rest) in HR and autonomic modulation between placebo and ATP condition. For RMSSD, there was a significant greater values for ATP compared to placebo (ATP=2.2±7.2 msec vs. placebo=−4.7±7.6 msec; *P*=0.009). In addition, delta analysis showed significant higher SDNN for ATP (ATP=3.1±10.8 msec vs. placebo=−2.9±8.5 msec, *P*=0.014). LFmsec^2^ was statistically lower for placebo in relation to ATP (ATP=−19.9±122.7 msec^2^ vs. placebo=−94.2± 200.3 msec^2^, *P*=0.028) and there was a trend to a significant difference in the HFmsec^2^ (ATP=5.1±77.6 msec^2^ vs. Placebo= −55.3±80.5 msec^2^, *P*=0.05).

[Fig. 3](#f3-jer-14-4-671){ref-type="fig"} presents the differences in blood pressure in placebo and ATP condition.

Regarding SBP (mmHg), there was a main effect of time (*F*=12.649, *P*\<0.001, *η*^2^=0.55), but no difference between conditions and interaction were verified (*P*\>0.05). However, when analyzed the delta (Δ=post-20 min minus rest), there was a significant lower SBP for ATP compared to placebo (ATP= −13.18±8.3 mm/Hg vs. placebo=−6.1±9.9 mm/Hg, *P*=0.006). For DBP (mmHg), there was no main effect of time, interaction and conditions (*P*\>0.05).

DISCUSSION
==========

To our knowledge, this was the first study to verify the effects of ATP supplementation on HRV and blood pressure after acute aerobic exercise in hypertensive women. The major finding of the present study were that a single dose of ATP supplementation increased parasympathetic modulation after exercise, and promoted a higher magnitude of the PEH with lower SBP compared to placebo after 20 min of aerobic exercise in hypertensive women.

The investigation about the influence of ATP supplementation on exercise performance is widely explored in the literature, demonstrating ergogenic effects ([@b9-jer-14-4-671]; [@b31-jer-14-4-671]; [@b41-jer-14-4-671]). Recently, our group investigated the acute influences of ATP supplementation on performance during resistance exercise (4 sets until muscular failure with 80% of one-repetition maximum in squat exercise) and physiological response in trained men. The results showed higher performance, oxygen consumption and energy expenditure with ATP supplementation compared with placebo ([@b9-jer-14-4-671]), however, the effect of acute ATP supplementation on blood pressure and autonomic modulation after exercise is unknown at the literature.

According our data, we observed that ATP supplementation potentiated the parasympathetic recovery after exercise, with higher RMSSD and delta LF values compared to placebo, demonstrating that ATP supplementation could contribute to autonomic modulation balance after exercise. In addition, changes in SDNN (delta) were higher for ATP in relation to placebo, which maybe occurred due to higher parasympathetic modulation for ATP condition while decreased for placebo, once both sympathetic and parasympathetic activity contribute to SDNN ([@b32-jer-14-4-671]; [@b36-jer-14-4-671]).

There is a relationship between reductions of rest parasympathetic modulation with ventricular arrhythmias and sudden cardiac death ([@b30-jer-14-4-671]; [@b38-jer-14-4-671]; [@b39-jer-14-4-671]). In addition, lower SDNN value is associated with a higher 5.3 times risk of mortality after acute myocardial infarction ([@b21-jer-14-4-671]) as well as lower RMSSD and SDNN are associated with higher cardiovascular disease and mortality risk ([@b34-jer-14-4-671]). Considering that, after exercise there is an increased risk of adverse effects in cardiac patients, for example as ischemia and ectopic heart activity ([@b35-jer-14-4-671]) and the parasympathetic modulation is lower ([@b4-jer-14-4-671]), our results may be a great clinical implication, once ATP supplementation could be used to recovery faster parasympathetic modulation after exercise, decreasing the risk of a cardiovascular event in cardiac patients following exercise.

Regarding blood pressure, both protocols induced PEH in the present study; however, ATP supplementation potentiated the magnitude of PEH, once our findings showed that changes in SBP (delta) was lower at 20 min after exercise in ATP condition than placebo. These findings have an important clinical repercussion, once the magnitude and duration of PEH are important for blood pressure control in hypertensive individuals ([@b10-jer-14-4-671]). We believe that the increase in parasympathetic modulation after exercise by ATP supplementation influenced blood pressure results, once PEH is mediated in part by the ANS ([@b10-jer-14-4-671]; [@b13-jer-14-4-671]; [@b22-jer-14-4-671]).

Another possible mechanism by ATP supplementation maybe influence blood pressure response is through the physiological effects of extracellular ATP on vascular tissue. During muscle contraction blood erythrocytes releases ATP which binds to the P2Y receptor in the endothelial tissue, inducing the production of substances with vasodilatation effects (endothelium-derived hyperpolarizing factor, prostacyclin, and nitric oxide), and thus relaxing the smooth muscle of the vasculature ([@b11-jer-14-4-671]). It has been reported that the maintenance of vasodilatation after exercise has a great impact on PEH ([@b13-jer-14-4-671]). In this sense, [@b15-jer-14-4-671] showed that ATP supplementation potentiated the blood flow after resistance exercise in rats and humans, suggesting that vasodilatory effects of extracellular ATP mediated these responses. Thus, we hypothesize that the reduction in SBP after exercise can be associated with vasodilatation induced by ATP supplementation. Supporting this, [@b40-jer-14-4-671] demonstrated that vascular introduction of P2Y (extracellular ATP receptor) agonist induced vasodilatation in a nitric oxide dependent-manner and reduced blood pressure in mice, suggesting that activation of purinergic signaling in endothelium may decrease the blood pressure.

From a practical point of view, the present study suggests that ATP supplementation can be used as a nutritional strategy to induced faster recovery of HRV after exercise by increasing parasympathetic modulation in hypertensive women. Thus, the results of this study may be applied by professionals to reduce the risk of a cardiovascular event in cardiac patients following exercise as well as may be used to potentiate the reduction of systolic blood pressure after exercise in individuals with hypertension. Despite the importance of our data, some limitations need to be considered: such as a small sample size and indirect HRV measurement as well as the HRV recovery was analyzed only during 30 min after exercise. Furthermore, the form and dose of ATP supplementation in the present study were well tolerated, and none of the participants reported adverse effects. Thus, we suggests future studies analyzing the influence of chronic ATP supplementation associated or no with exercise on blood pressure and HRV in cardiac patients.

In conclusion, a single dose of ATP supplementation reduced systolic blood pressure after aerobic exercise. In addition, our results showed that ATP supplementation induced faster recovery of HRV, increasing the parasympathetic modulation after a bout of moderate aerobic exercise in hypertensive women.
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![Experimental design. BP, blood pressure; HRV, heart rate variability; SUP, 400 mg of ATP or placebo; ATP, adenosine-5'-triphosphate; HRmax, maximum heart rate.](jer-14-4-671f1){#f1-jer-14-4-671}

![Comparison on delta heart rate and heart rate variability. (A) Delta (recovery minus rest) of the square root of the mean squared difference between adjacent RR intervals (RMSSD, ms). (B) Delta of the standard deviation of all normal RR intervals (SDNN, ms). (C) Delta of the low frequency (LF, ms^2^). (D) Delta of the high frequency (HF, ms^2^). (E) Delta of the heart rate. (F) Delta of the LF/HF ratio. ATP, adenosine-5'-triphosphate. \*Statistically significantly differences between ATP and placebo conditions.](jer-14-4-671f2){#f2-jer-14-4-671}

![Comparison on systolic and diastolic blood pressure for ATP and Placebo conditions. (A) Systolic blood pressure across time (SBP, mmHg). (B) Diastolic blood pressure across time (DBP, mmHg). (C) Delta of systolic blood pressure (Post-20 min of recovery minus rest). (D) Absolute variation on diastolic blood pressure (Post-20 min of recovery minus rest). a, main effect of time with difference between rest; b, main effect of time with difference between 5 min. ATP, adenosine-5'-triphosphate.](jer-14-4-671f3){#f3-jer-14-4-671}

###### 

General characteristics and dietary intake of the sample (n=11)

  Characteristic                Value
  ----------------------------- ------------
  Age (y)                       61.8±5.0
                                
  Height (cm)                   161.8±0.05
                                
  Weight (kg)                   67.7±10.3
  Body mass index (kg/m^2^)     26.0±2.9
                                
  Dietary intake pre-exercise   
   Diet carbohydrate (g)        40.4±28.5
   Diet protein (g)             7.4±4.5
   Diet lipids (g)              8.1±7.5
   Total intake (kcal)          257±170
                                
  Exercise intensity (%HRmax)   
   Placebo                      73.1±2.0
   ATP                          73.5±3.2

Values are presented as mean±standard deviation.

%HRmax, percentage of maximum heart rate; ATP, adenosine-5′-triphosphate.

###### 

Comparison on heart rate and heart rate variability

  Variable           Rest          Placebo recovery                                        ATP recovery
  ------------------ ------------- ------------------------------------------------------- -------------------------------------------------------
  Heart rate (bpm)   69.8±9.3      83.3±4.5[a)](#tfn5-jer-14-4-671){ref-type="table-fn"}   79.5±9.9[a)](#tfn5-jer-14-4-671){ref-type="table-fn"}
  SDNN (msec)        30.5±13.1     27.5±8.2                                                33.6±12.9
  RMSSD (msec)       16.4±8.5      11.6±4.0                                                18.5±9.7[b)](#tfn6-jer-14-4-671){ref-type="table-fn"}
  LF (msec^2^)       249.8±231.3   155.6±119.0                                             229.9±163.6
  HF (msec^2^)       104.1±84.9    48.83±30.1                                              109.2±106.4
  LF/HF ratio        2.32±1.0      3.35±1.5                                                3.83±2.3
  LF (nu)            60.43±22.1    71.9±9.2                                                68.33±9.4
  HF (nu)            33.52±11.4    28.04±9.3                                               31.31±9.3

Values are presented as mean±standard deviation.

ATP, adenosine-5′-triphosphate; SDNN, standard deviation of all normal RR intervals; RMSSD, square root of the mean squared difference between adjacent RR intervals; LF, low frequency; HF, high frequency.

Statistically significantly differences from rest.

Statistically significantly differences between ATP and placebo conditions.
